Study on How Faster Biological Aging Affects the Risk of Type 2 Diabetes in People With and Without Metabolic Liver Disease

What this Trial Is About

Researchers are investigating how biological aging relates to the risk of developing type 2 diabetes mellitus T2DM, especially in people with and without metabolic dysfunction-associated steatotic liver disease MASLD. They are measuring biological age using methods like phenotypic age, Klemera-Doubal method, and homeostatic dysregulation to see how aging affects diabetes risk. This observational study evaluates these associations using various statistical models to better understand the link between aging and T2DM incidence over time. Participants are grouped based on whether they have MASLD at the start of the study or not. The study collects data from annual health check-ups, including abdominal ultrasound and metabolic indicators like body mass index, blood pressure, cholesterol levels, and blood sugar measurements. No experimental treatments are given, as this is an observational study monitoring participants over an average of three years. During the study, researchers will track the onset of type 2 diabetes by reviewing health records and metabolic data collected yearly. They will assess the incidence of T2DM and analyze how biological aging measures correspond with disease development. The primary outcome is the incidence of new T2DM cases through the study completion. Participants will be observed for about three years, with no interventions applied, allowing researchers to monitor natural disease progression and aging effects.

Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population